Biomarkers in Solid Tumors: What’s on the Horizon?

Biomarker testing in oncology is an area of rapid growth. Practitioners need to be aware of new techniques that are being developed for detection of genomic alterations, and should also be aware of ongoing clinical trials that use novel trial designs and methodology for development of biomarker tests and targeted therapies.

Target Audience

This activity is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with solid tumors.

Learning Objectives

Following this program, participants should be able to:

  • Explain what is meant by tumor heterogeneity.
  • Review an example of a novel technique for biomarker detection.
  • Review advanced application of single cell analysis and liquid biopsy.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals Inc.
  • Eisai
  • Exact Sciences
  • Genentech, a member of the Roche Group
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Lilly
  • Novartis

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Merck & Co., Inc.

This activity is supported by an independent medical education grant from Illumina Corporate Foundation.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
12/20/2021
Course expires: 
12/20/2022
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2021 Virtual Congress: Biomarkers in Solid Tumors

Jennifer J.D. Morrissette, PhD
Abramson Cancer Center at the University of Pennsylvania

Aparna R. Parikh, MD, MS
Massachusetts General Hospital Cancer Center

David T. Ting, MD 
Massachusetts General Hospital Cancer Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Congress Co-Chairs

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Kimberly H. Allison, MD
Devicor Medical Products, Inc.: Consulting Fee 

Jennifer J.D. Morrissette, PhD
Bayer HealthCare: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

Presenting Faculty 

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Aparna R. Parikh, MD, MS
Bristol-Myers Squibb Company: Grant/Research Support
C2i Genomics: Equity Interest/Stock Options
Checkmate Pharmaceuticals: Consulting Fee  
Daiichi-Sankyo Co.: Grant/Research Support
Eli Lilly and Company: Consulting Fee
Genentech, Inc.: Grant/Research Support
Inivata Ltd.: Consulting Fee 
Mirati Therapeutics Inc.: Grant/Research Support 
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Consulting Fee 
Plexxikon: Grant/Research Support 
PMV Pharmaceuticals, Inc.: Grant/Research Support 
PureTech Health: Grant/Research Support
Roche Pharmaceuticals: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support 

David T. Ting, MD
Advanced Cell Diagnostics, Inc. (Bio-Techne): Grant/Research Support
Foundation Medicine, Inc.: Consulting Fee
Nanostring Technologies: Honoraria
PanTher Therapeutics: Equity Interest/Stock Options; Officer, Director or Any Other Fiduciary Role
Pfizer Inc.: Consulting Fee
PureTech Health: Grant/Research Support
Ribon Therapeutics: Grant/Research Support
ROME Therapeutics: Consulting Fee; Equity Interest/Stock Options; Intellectual Property Rights; Royalty Income; Scientific Advisor 
TellBio, Inc.: Equity Interest/Stock Options

NCCN Staff Disclosures 

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-136-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until December 20, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing